8-K: Aquestive Therapeutics Provides Business Update, Outlines 2025 Objectives

Aquestive Therapeutics is on track to submit its Anaphylm NDA in Q1 2025 and begin a Phase 2a trial for AQST-108 in Q2 2025, with approximately $70 million in cash as of December 31, 2024.

Summary

• Aquestive Therapeutics provided a business update and outlined key objectives for 2025.
• The company estimates it had approximately $70 million in cash and cash equivalents as of December 31, 2024.
• Aquestive is on track to submit the New Drug Application (NDA) for Anaphylm (epinephrine) Sublingual Film in the first quarter of 2025.
• They are actively recruiting subjects for the Anaphylm pediatric clinical trial.
• Aquestive successfully completed a pre-Investigational New Drug (IND) meeting for AQST-108 (epinephrine) Topical Gel and plans to begin a Phase 2a clinical trial for alopecia areata in the second quarter of 2025.
• The company received Orphan Drug Exclusivity for Libervant (diazepam) Buccal Film for patients between two to five years of age until April 2031.
• Aquestive is focused on preparing for the potential approval and launch of Anaphylm in the U.S. as early as the first quarter of 2026.
• They are also pursuing an ex-U.S. development strategy for Anaphylm and expanding sales of Libervant for younger patients.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with significant progress in clinical trials and product development. The company has a strong cash position and is on track to meet key milestones. However, there are inherent risks in the pharmaceutical industry, which temper the overall sentiment.

Positives

• The company has a strong cash position of approximately $70 million.
• Anaphylm is progressing towards NDA submission with a clear regulatory pathway.
• The pediatric trial for Anaphylm is underway, expanding its potential market.
• AQST-108 has shown promising results in early trials with no serious adverse events.
• Libervant has secured Orphan Drug Exclusivity, providing market protection.
• The company has a diversified pipeline with multiple products in development.
• Aquestive has a strong manufacturing capability with over 2 billion doses distributed.
• Anaphylm has demonstrated rapid absorption and consistent pharmacokinetics.
• The company has a dedicated and experienced leadership team.
• The company has a strong intellectual property portfolio with over 150 patents.

Negatives

• The estimated cash balance is preliminary and unaudited, subject to change.
• The actual financial results may differ materially from the preliminary estimates.
• There are risks associated with the regulatory approval process for Anaphylm and AQST-108.
• The company faces competition from existing products and potential generics.
• There is a risk of loss of U.S. market approval for Libervant due to legal challenges.
• The company is reliant on the success of its pipeline products for future growth.
• There is a risk of eroding market share for Suboxone, a significant revenue source.
• The company faces risks related to manufacturing, supply chain, and intellectual property.
• There are risks related to the outsourcing of certain sales and marketing functions.
• The company is subject to general economic, political, and market conditions.

Risks

• There are risks associated with the development and clinical trials of Anaphylm and AQST-108, including potential delays or changes in timing and cost.
• The company may not receive FDA approval for its product candidates, including Anaphylm and AQST-108.
• Aquestive may not generate sufficient clinical data for approval of its product candidates.
• The company may not overcome the orphan drug market exclusivity of a competing product for Libervant.
• There is a risk of loss of U.S. market approval for Libervant due to legal challenges.
• The company faces risks related to commercializing new products, including market acceptance and competition.
• Aquestive may not have sufficient capital and cash resources to fund its operations and development activities.
• There is a risk of eroding market share for Suboxone, which is a significant revenue source.
• The company faces risks related to manufacturing, supply chain, and intellectual property.
• There are risks related to claims and legal proceedings against Aquestive.

Future Outlook

Aquestive is focused on the potential approval and launch of Anaphylm in the U.S. as early as the first quarter of 2026, expanding the development of Anaphylm and AQST-108 outside the U.S., and continuing to expand sales of Libervant. They also plan to submit an NDA and launch Libervant for epilepsy patients between 6 to 11 years of age, if approved by the FDA, upon the expiration of the existing orphan drug market exclusivity scheduled to expire in January 2027.

Management Comments

• Dan Barber, President and Chief Executive Officer of Aquestive, stated that the company significantly advanced in 2024 and delivered on key milestones.
• He believes the company's long-term growth strategy remains compelling with the potential approval and launches of Anaphylm, Libervant (patients 6+), and AQST-108.

Industry Context

This announcement highlights Aquestive's progress in the pharmaceutical industry, particularly in the development of innovative drug delivery systems. The focus on epinephrine delivery for anaphylaxis and topical treatments for alopecia areata addresses significant unmet medical needs. The company is positioning itself to compete with existing treatments and capture market share in these areas.

Comparison to Industry Standards

• The development of Anaphylm as an orally delivered epinephrine product is a novel approach compared to the standard of care, which is epinephrine auto-injectors (EAIs) like EpiPen and Auvi-Q.
• The company's focus on a sublingual film delivery method for epinephrine is unique and aims to address the limitations of current device-based treatments.
• The development of AQST-108 as a topical treatment for alopecia areata is an alternative to systemic treatments like JAK inhibitors, which have known side effects and black box warnings.
• The company's Libervant product is positioned as an alternative to device-based products like rectal gel and nasal sprays for the treatment of seizure clusters in pediatric patients.
• The company's PharmFilm technology is a leading oral thin film delivery system, with over 2 billion doses distributed worldwide, demonstrating a strong manufacturing capability.

Stakeholder Impact

• Shareholders: The positive progress in product development and financial stability are likely to be viewed favorably by shareholders.
• Patients: The development of Anaphylm and AQST-108 addresses unmet medical needs and offers potential new treatment options.
• Employees: The company's growth and progress may provide job security and opportunities for advancement.
• Customers: The company's products, including Libervant, provide essential treatments for patients with epilepsy.
• Suppliers: The company's manufacturing activities support the supply chain and create business opportunities for suppliers.
• Creditors: The company's strong cash position and progress in product development may reduce credit risk.

Next Steps

• Submit the NDA for Anaphylm in Q1 2025.
• Continue recruiting subjects for the Anaphylm pediatric clinical trial.
• Begin the Phase 2a clinical trial for AQST-108 in alopecia areata in Q2 2025.
• Prepare for the potential approval and launch of Anaphylm in the U.S. as early as Q1 2026.
• Pursue ex-U.S. development strategy for Anaphylm.
• Expand sales of Libervant for younger patients.
• Submit an NDA and launch Libervant for epilepsy patients between 6 to 11 years of age, if approved by the FDA, upon the expiration of the existing orphan drug market exclusivity scheduled to expire in January 2027.

Key Dates

Keywords

Anaphylm, epinephrine, AQST-108, Libervant, alopecia areata, pharmaceutical, clinical trial, FDA, NDA, orphan drug exclusivity, oral thin film, seizure clusters, anaphylaxis